Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
1,894 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Ultra-processed food consumption and cancer risk: A systematic review and meta-analysis.
Isaksen IM, Dankel SN · Clin Nutr · 2023Meta-Analysis, Systematic Review
- An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data.
Lancet Oncol · 2016Meta-Analysis
- Zanubrutinib in B-cell malignancies.
Das M · Lancet Oncol · 2019Clinical Trial, Phase I, Multicenter Study
- First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial.
Moreno C, Greil R, Demirkan F, et al. · Haematologica · 2022Clinical Trial, Phase III, Randomized Controlled Trial
- Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
Al-Sawaf O, Zhang C, Tandon M, et al. · Lancet Oncol · 2020Clinical Trial, Phase III, Multicenter Study
- Safety profile of first-line targeted therapies in elderly and/or comorbid chronic lymphocytic leukaemia patients (unfit subpopulation). A systematic review and network meta-analysis.
Stożek-Tutro A, Reczek M, Kawalec P · Crit Rev Oncol Hematol · 2024Systematic Review, Network Meta-Analysis
- Integrative Bulk and Single-Cell Profiling of Premanufacture T-cell Populations Reveals Factors Mediating Long-Term Persistence of CAR T-cell Therapy.
Chen GM, Chen C, Das RK, et al. · Cancer Discov · 2021Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Measurable Residual Disease and Clinical Outcomes in Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis.
Rios-Olais FA, McGary AK, Tsang M, et al. · JAMA Oncol · 2024Systematic Review, Meta-Analysis
- Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
Jones JA, Mato AR, Wierda WG, et al. · Lancet Oncol · 2018Clinical Trial, Phase II, Multicenter Study
- Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC, Czuczman M, Salles G, et al. · Lancet Oncol · 2015Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Chronic lymphocytic leukemia international prognostic index: a systematic review and meta-analysis.
Molica S, Giannarelli D, Mirabelli R, et al. · Blood · 2018Letter, Meta-Analysis
- Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia.
Ohmoto A, Fuji S, Shultes KC, et al. · Bone Marrow Transplant · 2022Meta-Analysis, Review
- mRNA COVID-19 vaccines in patients with chronic lymphocytic leukemia: A systematic review and meta-analysis.
Molica S, Giannarelli D, Montserrat E · Eur J Haematol · 2022Letter, Meta-Analysis
- Assessment of the effect of ofatumumab on cardiac repolarization.
Jewell RC, Laubscher K, Lewis E, et al. · J Clin Pharmacol · 2015Clinical Trial, Phase I, Clinical Trial, Phase III
- Clinical Research in Chronic Lymphocytic Leukemia in Pakistan; A Systematic Review.
Ammad Ud Din M, Shahzad M, Ashraf A, et al. · Medicina (Kaunas) · 2023Systematic Review
- Randomized controlled trials in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis.
Police RL, Trask PC, Wang J, et al. · Clin Lymphoma Myeloma Leuk · 2015Meta-Analysis, Research Support, Non-U.S. Gov't
- COVID-19 among fit patients with CLL treated with venetoclax-based combinations.
Fürstenau M, Langerbeins P, De Silva N, et al. · Leukemia · 2020Clinical Trial, Phase III, Multicenter Study
- Prognostic models for chronic lymphocytic leukemia (CLL): a systematic review and meta-analysis.
Molica S, Giannarelli D · Leukemia · 2021Meta-Analysis, Systematic Review
- Outcomes of COVID-19 infection in patients with chronic lymphocytic leukemia: a systematic review and meta-analysis.
Akbarzadeh MA, Vaez-Gharamaleki Y, Jahanshahlou F, et al. · Rev Assoc Med Bras (1992) · 2024Systematic Review, Meta-Analysis
- Priapism in Lymphoproliferative Disorders: A Systematic Review.
Ali EA, Sardar S, Yassin MA · Hematol Oncol Stem Cell Ther · 2022Systematic Review
- Chronic lymphocytic leukemia and autoimmunity: a systematic review.
Hodgson K, Ferrer G, Montserrat E, et al. · Haematologica · 2011Research Support, Non-U.S. Gov't, Systematic Review
- Chronic Lymphocytic Leukemia-Induced Humoral Immunosuppression: A Systematic Review.
Grywalska E, Zaborek M, yczba J, et al. · Cells · 2020Research Support, Non-U.S. Gov't, Systematic Review
- ZAP-70 in chronic lymphocytic leukemia: A meta-analysis.
Liu Y, Wang Y, Yang J, et al. · Clin Chim Acta · 2018Meta-Analysis, Review
- Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis.
Liang L, Zhao M, Zhu YC, et al. · Ann Hematol · 2016Meta-Analysis, Systematic Review
- Efficacy and safety of phosphatidylinositol 3-kinase inhibitors in patients with chronic lymphocytic leukemia: a meta-analysis and systematic review.
Wen Y, Meng L, Zhang X, et al. · Expert Rev Hematol · 2022Meta-Analysis, Systematic Review
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.